StockWatch
·

Gujarat Fluorochemicals Ltd Q2 FY27 Results

FLUOROCHEMQ2 FY27 Results
Filing
Result:Good· Market: Up#Margin squeeze#Base effect

Beat/Miss: Beat · Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue1.8K10.8%45.5%
Total Income1.8K10.6%45.6%
Expenditure1.4K11.1%47.5%
PBT339.008.7%37.8%
Net Profit240.009.6%34.1%
OPM26.88%0.07pp3.20pp
NPM13.56%0.13pp1.16pp
EPS22.119.6%35.6%
View full financials

Chemicals-segment revenue growth of 43% YoY and a street beat on revenue/PAT/margin are offset by EBITDA margin still down ~280bps YoY (26.9% vs 29.6%), capping this below very_good.

GUJARAT FLUOROCHEMICALS · Q2 FY-2027 · THE VERDICT

Growth beats fluoropolymer guide, but battery losses and capex delays mask the picture

Revenue and profit both rose 45% and 34% YoY, and fluoropolymer beat guidance by 2 percentage points. But battery materials are still losing ₹50 crore and capex execution is already slipping.

06 Nov 2026 · 6 min read
Revenue

₹1,760 Cr

+45.5% YoY; +10.8% QoQ

PAT

₹240 Cr

+34.1% YoY; +9.6% QoQ

Chemical segment PAT

₹290 Cr

+46% YoY

Battery segment loss

~₹50 Cr

in loss phase

The headline reads strong: revenue up 45.5% YoY to ₹1,760 crore, profit up 34.1% to ₹240 crore. Fluoropolymer beat its own guidance, delivering 22% growth versus the 17–20% target. But dig deeper and the earnings mask a buried story. The chemical segment's 46% PAT growth is real. The consolidated 34% is held back entirely by battery losses. Battery materials are currently burning ₹~50 crore — the gap between chemical segment profit (₹290 crore) and consolidated profit (₹240 crore). And the capex plan that's supposed to unlock battery scale is already slipping: the Oman project delayed 1–1.5 quarters, LFP expansion deferred, anode deprioritized. For a stock trading near its all-time high and held mostly by promoters and institutions, this is the tension that matters.

Where the growth came from

Fluoropolymer drove the quarter with ₹931 crore, up 22% YoY, momentum accelerating in automotive seals (FKM), polysulfone (PSA), and semiconductors. Fluorochemicals nearly tripled to ₹607 crore on the global shift from R-410A to R-32 refrigerants; management expects full capacity by Q3 FY27 and R-134A production by Q4 FY27. Together they deliver the reported ₹1,723 crore chemical segment revenue and ₹290 crore PAT. The rest is battery materials, currently in loss. LiPF6 has signed 5 major global electrolyte OEMs with multi-year volume binding. PVDF and PTFE grades are in advanced customer trial. The company guidance says 3-digit revenue by Q4 FY27, but the units are not yet commercial. Profitability is expected mid-FY28 after electrolyte ramps in India.

Q2 FY27 Revenue by segment, ₹ Cr
0347.57695.151,042.72931Fluoropolymer607Fluorochemicals151Bulk Chemicals
Fluorochemicals surged 135% YoY on R-32 demand. Bulk Chemicals fell 5% YoY due to caustic soda price collapse and higher captive R-32 consumption.

Management's core claims — what holds up

Five assertions on the call, graded against the numbers.

Fluoropolymer 22% beats 17–20% guidance

₹931 Cr vs ₹764 Cr YoY = 22%. Guidance reaffirmed, not raised.

Supported

Chemical segment PAT +46% YoY to ₹290 Cr

Disclosed. Consolidated PAT ₹240 Cr implies battery loss ₹~50 Cr.

Supported

EBITDA margin 27%, resilient

₹473 Cr EBITDA on ₹1,760 Cr revenue = 26.9%. Margin flat YoY and QoQ.

Supported

Battery 3-digit Q4 FY27 revenue on track

LiPF6 in trial with 5 OEMs; commercial supplies expected Q4. Not yet realized.

Supported (not yet achieved)

FY27 capex ₹3,100 Cr on track

Oman delayed 1–1.5 quarters, shifted to India. LFP deferred. Spend tracking into FY28.

Overstated

What changed on this call

Fluoropolymer beat. The 22% growth versus 17–20% signals sustained momentum in high-value applications (automotive, semiconductors, data centers). Management is confident; guidance reaffirmed, not raised. Bulk Chemicals down 5%. Caustic soda prices collapsed globally; higher captive consumption for R-32 production. Temporary. Battery profitability timeline shifted. Still losing ₹~50 crore. Electrolyte ramp in India moved from FY27 to mid-FY28. 3-digit Q4 FY27 revenue expected, but path to positive PAT is now 12+ months away. Capex execution slipping. Oman project on hold, capacity pivoted to India — 1–1.5 quarter delay. LFP expansion deferred. Anode deprioritized ('not a priority right now'). Analysts pressed; management acknowledged delays but held guidance.

Price and market positioning

As of 2026-11-05, the stock trades at ₹4,709.6 — up 61.5% from the 52-week low but 5.0% below its all-time high of ₹4,958.9. It sits above its 20-, 50-, and 200-day moving averages (₹4,414, ₹4,517, ₹3,894), confirming sustained bullish momentum. RSI at 63.3 is neutral (not extended). Volume is normal. Foreign investors hold 4.41% (up 0.13pp QoQ), domestic institutions 13.33% (down 0.16pp), promoters 61.39% (unchanged). This ownership split — promoter-dominated, stable institutions — suggests the stock is held by long-term believers, not momentum traders.

The bull-bear ledger
  • Fluoropolymer beat 17–20% guidance at 22%; high-value segments accelerating

  • R-32 platform +135% YoY; full utilization expected Q3 FY27

  • EBITDA margin 27% stable despite input volatility and battery drag

  • Battery materials signed 5 major global OEMs with volume binding

  • Battery segment currently ₹~50 Cr loss; profitability deferred to mid-FY28

  • Capex execution slipping — Oman 1–1.5 Q delay, anode deprioritized

  • LiPF6 pricing down 33% in one month from China; margin protected by lithium pass-through but volume tail risk

  • Bulk Chemicals down 5% YoY; caustic soda deflation is temporary headwind

Risks — ranked by holder concern

Five issues that matter most if you own this stock.

Capex execution delays compound

High

Oman on hold 1–1.5 quarters, shifted to India. LFP deferred. Anode deprioritized. ₹3,100 Cr FY27 target slipping into FY28. Cascading delays cascade — if the sequence breaks, multi-year ₹6,000 Cr capex becomes unachievable at guided pace.

Battery profitability timeline extends

High

Currently ₹~50 Cr loss. Electrolyte ramp pushed to mid-FY28. If domestic EV adoption in India is slower or customer qualifications extend, profitability slips another 1–2 quarters. Further depresses consolidated earnings and capex ROI.

LiPF6 pricing deflation from China persists

Medium

Prices fell 33% in one month (₹150K to ₹100K per unit). Lithium pass-through protects margin, but tail risk if prices floor below cost or if customers switch suppliers. Sustained deflation erodes volume confidence.

Domestic battery demand ramps slower than mid-FY28

Medium

Current Indian battery production 'very, very low' on GWh basis. Electrolyte ramp depends on OEM plant stabilization and customer timelines. If domestic EV cycle is slower, capex utilization will be lower and profitability delayed further.

Bulk Chemicals margin pressure persists

Low

Down 5% YoY. Caustic soda deflation and captive R-32 consumption. Temporary; will recover if R-32 ramp stabilizes and caustic prices normalize. Low urgency if core segments hold.

What to watch next
  • 1 · R-32 utilization Q3 FY27

    Management guided full capacity by Q3 FY27. If delivered, it confirms refrigerant upside and stabilizes bulk chemicals margin. Watch the Q3 press release.

  • 2 · Battery 3-digit Q4 FY27 revenue

    Guided for Q4 FY27 (Jan–Mar 2027). This is the proof point that LiPF6 trials have converted to commercial sales. If it happens, battery bull case resets. If it slips, credibility erodes.

  • 3 · Capex execution and FY28 spend

    Next quarterly call will show whether India-based capex shift is real and on schedule, or whether 1–1.5 quarter delay becomes 2+ quarters. This resolves multi-year capex plan viability.

Gujarat Fluorochemicals is a well-positioned chemical franchise with genuine long-term optionality in battery materials. This quarter confirms fluoropolymer acceleration and R-32 platform strength. It also confirms that battery is unprofitable, capex execution is slipping, and the timeline to guided profitability is narrowing. The stock trades 5% below its all-time high, held by promoters and institutions, and sits above all moving averages. The market is still optimistic on battery upside — and the contracts are real. But holders should watch three things closely: the rate at which capex delays accumulate, whether battery profitability actually narrows the loss in Q3–Q4, and whether management's Q4 3-digit revenue and mid-FY28 electrolyte ramp actually materialize. On that clarity, this Hold will either firm into a Buy or slip into a Sell. The single number to track from here is battery segment loss — not when it turns positive, but by how much it shrinks over the next two quarters.

Informational and educational content only. Not investment advice.